Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Oxford BioMedica ( (GB:OXB) ).
Oxford Biomedica has confirmed that its issued share capital at the close of business on 31 March 2026 comprised 120,900,850 ordinary shares, with none held in treasury. As a result, the company’s total number of voting rights is 120,900,850, a figure shareholders must use when assessing whether they are required to disclose holdings or changes under UK transparency rules.
The most recent analyst rating on (GB:OXB) stock is a Sell with a £543.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a UK-headquartered, quality- and innovation-led contract development and manufacturing organisation specialising in cell and gene therapy. With around 30 years of experience in viral vectors, it provides development and manufacturing services across lentiviral, AAV, adenoviral and other vector platforms, supporting clients from early-stage development through to commercialisation across sites in the UK, France and the U.S.
Average Trading Volume: 384,939
Technical Sentiment Signal: Buy
Current Market Cap: £666M
For detailed information about OXB stock, go to TipRanks’ Stock Analysis page.